SCANDION ONC. DK-0735 (F:8VY) — Market Cap & Net Worth

$140.86K USD  · €120.48K EUR  · Rank #31269

Market Cap & Net Worth: SCANDION ONC. DK-0735 (8VY)

SCANDION ONC. DK-0735 (F:8VY) has a market capitalization of $140.86K (€120.48K) as of August 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #31269 globally and #2792 in its home market, demonstrating a 0.00% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying SCANDION ONC. DK-0735's stock price €0.00 by its total outstanding shares 234762000 (234.76 Million).

SCANDION ONC. DK-0735 Market Cap History: 2021 to 2025

SCANDION ONC. DK-0735's market capitalization history from 2021 to 2025. Data shows change from $325.51 Million to $164.68K (-83.46% CAGR).

SCANDION ONC. DK-0735 Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how SCANDION ONC. DK-0735's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

No P/S ratio data available

Latest Price to Earnings (P/E) Ratio

No P/E ratio data available

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
No financial ratio data available

Competitor Companies of 8VY by Market Capitalization

Companies near SCANDION ONC. DK-0735 in the global market cap rankings as of August 4, 2026.

Key companies related to SCANDION ONC. DK-0735 by market ranking:

  • Lexington Gold Ltd (LSE:LEX): Ranked #31260 globally with a market cap of $145.51K USD ( GBX1.20 Billion GBX).
  • MYCELX Technologies Corporation (LSE:MYX): Ranked #31261 globally with a market cap of $145.25K USD ( GBX1.19 Billion GBX).
  • Xtract Resources PLC (LSE:XTR): Ranked #31270 globally with a market cap of $140.66K USD ( GBX1.16 Billion GBX).
  • Fulcrum Metals PLC (LSE:FMET): Ranked #31271 globally with a market cap of $140.19K USD ( GBX1.15 Billion GBX).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#31260 Lexington Gold Ltd LSE:LEX $145.51K GBX2.85
#31261 MYCELX Technologies Corporation LSE:MYX $145.25K GBX49.00
#31270 Xtract Resources PLC LSE:XTR $140.66K GBX1.35
#31271 Fulcrum Metals PLC LSE:FMET $140.19K GBX7.50

SCANDION ONC. DK-0735 Historical Marketcap From 2021 to 2025

Between 2021 and today, SCANDION ONC. DK-0735's market cap moved from $325.51 Million to $ 164.68K, with a yearly change of -83.46%.

Year Market Cap Change (%)
2025 €164.68K -90.91%
2024 €1.81 Million -97.93%
2023 €87.42 Million +61.68%
2022 €54.07 Million -83.39%
2021 €325.51 Million --

End of Day Market Cap According to Different Sources

On Jul 10th, 2026 the market cap of SCANDION ONC. DK-0735 was reported to be:

Source Market Cap
Yahoo Finance $140.86K USD
MoneyControl $140.86K USD
MarketWatch $140.86K USD
marketcap.company $140.86K USD
Reuters $140.86K USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About SCANDION ONC. DK-0735

F:8VY Germany
Market Cap
$164.68K
€140.86K EUR
Market Cap Rank
#31269 Global
#2792 in Germany
Share Price
€0.00
Change (1 day)
+0.00%
52-Week Range
€0.00 - €0.00
All Time High
€2.18
About

Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for tr… Read more